Mark Faupel, who was named chief operating officer and chief technical officer in January, is the new chief executive officer of SpectRx.

Faupel joined SpectRx in January. He replaces Mark Samuels as CEO. Faupel has worked with the company since 1998.

“I am very pleased and excited with the opportunity the board has given me and the prospect of working with our team to bring this potentially life-saving technology to market,” Faupel said. “The company is focused on completing the tasks necessary to deliver the product to market, namely, completing our FDA pivotal clinical trials, obtaining necessary regulatory approvals and international quality marks, completing product design and manufacturing work and market launch.”

Faupel is an inventor involved in 15 patents.

SpectRx is developing detection, monitoring and treatment solutions for use in cancer and diabetes patients.